MX2010000938A - Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. - Google Patents

Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000938A
MX2010000938A MX2010000938A MX2010000938A MX2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A
Authority
MX
Mexico
Prior art keywords
benzothiazol
morpholin
piperidine
methoxy
amide
Prior art date
Application number
MX2010000938A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000938A publication Critical patent/MX2010000938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para tratar el trastorno por stress postraumático en un paciente con ácido 4-hydroxi-4-metíl-piperidin-1-carboxilico (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida. También se proveen métodos para mejorar la capacidad de recuperación del paciente con ácido 4-hidroxi-4-metil-piperidin-1-carboxilico (4-metoxi-7-morfolin-4-il-beazotiazol-2-il)-amida. También se proveen métodos para diagnosticar el trastorno postraumático en un paciente.
MX2010000938A 2007-07-23 2008-07-23 Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. MX2010000938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503507P 2007-07-23 2007-07-23
PCT/US2008/070934 WO2009015236A1 (en) 2007-07-23 2008-07-23 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000938A true MX2010000938A (es) 2010-07-01

Family

ID=40281808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000938A MX2010000938A (es) 2007-07-23 2008-07-23 Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090082341A1 (es)
EP (1) EP2182803A4 (es)
JP (1) JP2010534674A (es)
CN (1) CN101873799A (es)
AU (1) AU2008279169A1 (es)
BR (1) BRPI0814672A2 (es)
CA (1) CA2708323C (es)
CO (1) CO6260011A2 (es)
MX (1) MX2010000938A (es)
NZ (1) NZ583191A (es)
RU (1) RU2500401C2 (es)
WO (1) WO2009015236A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183696A1 (en) * 2007-08-06 2012-09-27 Biotie Therapies Inc Medicaments comprising nepicastat for use in treating dependence on a substance
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100571161B1 (ko) * 2000-06-21 2006-04-17 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1631294B1 (en) * 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
PL1753760T3 (pl) * 2004-05-24 2008-06-30 Hoffmann La Roche (4-metoksy-7-morffolin-4-ylobenzatiazol-2-ilo)amid kwasu 4-hydroksy-4-metylopiperydyno-1-karboksylowego
RU2328977C2 (ru) * 2007-01-15 2008-07-20 Наталья Леонидовна Бундало Способ диагностики посттравматического стрессового расстройства (птср)
MX2010000937A (es) * 2007-07-23 2010-06-25 Synosia Therapeutics Inc Tratamiento del trastorno por estrés postraumático.

Also Published As

Publication number Publication date
AU2008279169A1 (en) 2009-01-29
CO6260011A2 (es) 2011-03-22
EP2182803A4 (en) 2010-09-01
WO2009015236A1 (en) 2009-01-29
CA2708323C (en) 2013-09-24
NZ583191A (en) 2012-06-29
US20090082341A1 (en) 2009-03-26
JP2010534674A (ja) 2010-11-11
BRPI0814672A2 (pt) 2014-09-30
RU2500401C2 (ru) 2013-12-10
CA2708323A1 (en) 2009-01-29
RU2010106023A (ru) 2011-08-27
CN101873799A (zh) 2010-10-27
EP2182803A1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
MY172372A (en) Compositions and methods for lowering triglycerides
MX2010006823A (es) Metodos para el tratamiento de la gota.
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX356873B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
MX2019003619A (es) Formulaciones de bromocriptina.
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
HK1152649A1 (zh) 患有輕度認知障礙需要治療的患者的鑒定方法以及這種患者的治療
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
NZ597115A (en) Method of treating age related disorders with fujimycin
EP2488507A4 (en) NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
WO2011067711A3 (en) Novel heparanase splice variant
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
MY179784A (en) Use of cathepsin h
UA37467U (en) Method for treating duodenogastroesophageal reflux
UA36750U (ru) Способ лечения лейкоплакии слизистой оболочки полости рта
UA56675U (ru) Способ местного лечения генерализованного пародонтита c использованием синглетно-кислородной терапии
UA45538U (ru) Способ лечения астенического синдрома у пациентов урологического профиля
UA37170U (ru) Способ профилактики и лечения тканевой гипоксии при резервировании аутокрови
UA58941U (ru) Способ оптимизации тактики восстановительного лечения больных глиальными опухолями головного мозга
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal